CALQUENCE ® (acalabrutinib) plus chemoimmunotherapy reduced the risk of disease progression or death by 27% vs. standard of care in patients with untreated mantle cell lymphoma in ECHO Phase III trial Read more
Swiss National Bank advances with Phase III of Helvetia CBDC pilot program By Investing.com Read more
Russia Calls for Prevention of ‘Full-Scale World War III’ — Official Warns ‘World Tensions Are White-Hot’ – Economics Bitcoin News Read more